Clinical Trial Update: Treatment of Patients With Nephrogenic Systemic Fibrosis With Glivec [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating imatinib (Glivec) for nephrogenic systemic fibrosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nephrogenic Systemic Fibrosis

Drugs mentioned

• Glivec (imatinib)

Snippet

Sponsor: University of Aarhus | Conditions: Nephrogenic Systemic Fibrosis | Phase 3 | Status: COMPLETED